par Colleoni, Marco Angelo;Luo, Weixiu;Karlsson, Per;Chirgwin, Jacquie;Aebi, Stefan;Jerusalem, Guy;Neven, Patrick 
;Hitre, Erika;Graas, Marie-Pascale;Simoncini, Edda;Kamby, Claus;Thompson, Alastair M;Loibl, Sibylle;Gavilá, Joaquín;Kuroi, Katsumasa;Marth, Christian;Müller, Bettina;O'Reilly, Seamus;Di Lauro, Vincenzo;Gombos, Andrea ;Ruhstaller, Thomas;Burstein, Harold;Ribi, Karin;Bernhard, Jürg;Viale, Giuseppe;Maibach, Rudolf;Rabaglio-Poretti, Manuela;Gelber, Richard D;Coates, Alan A.S.;Di Leo, Angelo ;Regan, Meredith;Goldhirsch, Aron;SOLE Investigators,
Référence Lancet oncology, 19, 1, page (127-138)
Publication Publié, 2018
;Hitre, Erika;Graas, Marie-Pascale;Simoncini, Edda;Kamby, Claus;Thompson, Alastair M;Loibl, Sibylle;Gavilá, Joaquín;Kuroi, Katsumasa;Marth, Christian;Müller, Bettina;O'Reilly, Seamus;Di Lauro, Vincenzo;Gombos, Andrea ;Ruhstaller, Thomas;Burstein, Harold;Ribi, Karin;Bernhard, Jürg;Viale, Giuseppe;Maibach, Rudolf;Rabaglio-Poretti, Manuela;Gelber, Richard D;Coates, Alan A.S.;Di Leo, Angelo ;Regan, Meredith;Goldhirsch, Aron;SOLE Investigators, Référence Lancet oncology, 19, 1, page (127-138)
Publication Publié, 2018
Article révisé par les pairs
| Résumé : | In animal models of breast cancer, resistance to continuous use of letrozole can be reversed by withdrawal and reintroduction of letrozole. We therefore hypothesised that extended intermittent use of adjuvant letrozole would improve breast cancer outcome compared with continuous use of letrozole in postmenopausal women. |
